TITLE

The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children

AUTHOR(S)
Ji Hyuk Lee; Mi Jin Kim; Jong Seung Lee; Yon Ho Choe
PUB. DATE
January 2011
SOURCE
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives The purpose of this 24-week treatment study was to evaluate the effects of three treatment strategies after 8 weeks of lansoprazole therapy for gastroesophageal reflux disease in children. Design Open-labelled, uncontrolled, prospective study. Setting Samsung Medical Center, Seoul, Korea. Methods 37 erosive reflux disease (ERD) and 20 non-erosive reflux disease (NERD) patients were divided into three groups by symptom assessment at 8 weeks: (1) observation without treatment in the 'symptoms-resolved⇔(tm) group, (2) 'on-demand⇔(tm) treatment for an additional 16 weeks in the 'symptoms-attenuated⇔(tm) group and (3) continuous treatment in the 'symptoms-persistent⇔(tm) group. Results For ERD, six (100%) out of six patients in the 'symptoms-resolved⇔(tm) group remained improved at weeks 16 and 24. Sixteen (72.7%) out of 22 patients in the 'symptoms-attenuated⇔(tm) group had improvement of symptoms at 16 weeks, and 18 (81.8%) patients at 24 weeks. Six (66.7%) out of nine patients in the 'symptoms-persistent⇔(tm) group remained improved at weeks 16 and 24. For NERD, seven (100%) out of seven patients in the 'symptoms-resolved⇔(tm) group remained improved at weeks 16 and 24. Eight (80.0%) out of 10 patients in the 'symptoms-attenuated⇔(tm) group remained improved at week 16, and 10 (100.0%) patients at week 24. None out of three patients in the 'symptoms-persistent⇔(tm) group remained improved at weeks 16 and 24. Conclusions The selection of each alternative for long-term management according to the results of the assessment of symptoms at week 8 was useful and well tolerated. 'On-demand⇔(tm) therapy was equally effective. The 16-week therapy had the same efficacy as the 24-week therapy with regard to long-term lansoprazole treatment.
ACCESSION #
60964148

 

Related Articles

  • The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children. Ji Hyuk Lee; Mi Jin Kim; Jong Seung Lee; Yon Ho Choe // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p9 

    Objectives The purpose of this 24-week treatment study was to evaluate the effects of three treatment strategies after 8 weeks of lansoprazole therapy for gastroesophageal reflux disease in children. Design Open-labelled, uncontrolled, prospective study. Setting Samsung Medical Center, Seoul,...

  • The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children. Ji Hyuk Lee; Mi Jin Kim; Jong Seung Lee; Yon Ho Choe // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p9 

    Objectives The purpose of this 24-week treatment study was to evaluate the effects of three treatment strategies after 8 weeks of lansoprazole therapy for gastroesophageal reflux disease in children. Design Open-labelled, uncontrolled, prospective study. Setting Samsung Medical Center, Seoul,...

  • A Primer on ... Sibley, Cate // Pediatrics for Parents;Nov/Dec2009, Vol. 25 Issue 11/12, p19 

    The article discusses the therapeutic uses of Prevacid, a proton pump inhibitor (PPI) which was approved by the Food and Drug Administration (FDA) in the U.S. It states that the drug is commonly used by physicians in treating infants and older children with gastroesophogeal reflux disease (GERD)...

  • Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD. Brian Jacobson // Digestive Diseases & Sciences;Sep2008, Vol. 53 Issue 9, p2313 

    Abstract  In studies of the association between obesity and gastroesophageal reflux, one subject that has received very little attention is the effect excess body mass may have on the effectiveness of acid-mediating agents. The lack of systematic research may reflect the perceived high...

  • PPIs FOR INFANTS WITH GERD.  // Clinical Advisor;Aug2010, Vol. 13 Issue 8, p34 

    The author reports that the hospital in which she works uses a histamine-2 blocker to treat infants with gastroesophageal reflux disease, followed by proton-pump inhibitor (PPI) if the treatment is unsuccessful.

  • Selection of Proton Pump Inhibitors (PPIs) for Formulary Inclusion Using an Objective Scoring System in Malaysia. Lim, Lynette; Mohamed, Izham M.I // Journal of Applied Pharmaceutical Science;2012, Vol. 2 Issue 3, p17 

    The main aim of this study was to develop an objective Drug Evaluation Scoring System (DESS) by determining criteria for differentiation among 5 PPI drugs available in the market i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. Secondly, was to assign weightage...

  • Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review. Monzani, Alice; Oderda, Giuseppina // Clinical & Experimental Gastroenterology;2010, Vol. 3, p17 

    Omeprazole is a proton-pump inhibitor indicated for gastroesophageal reflux disease and erosive esophagitis treatment in children. The aim of this review was to evaluate the efficacy of delayed-release oral suspension of omeprazole in childhood esophagitis, in terms of symptom relief, reduction...

  • ENDOSCOPIC GASTROPLICATION FOR THE TREATMENT OF PAEDIATRIC GASTRO-OESOPHAGEAL REFLUX DISEASE: 12 MONTH FOLLOW UP RESULTS. Thomson, M. A.; Hall, S.; Fritscher-Ravens, A.; Swain, P. // Gut;Apr2004 Supplement 3, Vol. 53, pA10 

    The aim of this work is to assess the medium term efficacy of the BARD Endocinch device for the treatment of gastro-oesophageal reflux disease (GORD) in children and adolescents. 17 males with symptoms of GORD dependent on proton pump inhibitors (PPI) for greater than 12 months or refractory to...

  • Esomeprazole: In Gastroesophageal Reflux Disease in Children and Adolescents. Croxtall, Jamie D.; Perry, Caroline M.; Keating, Gillian M. // Pediatric Drugs;2008, Vol. 10 Issue 3, p199 

    â–´ Esomeprazole is the S-isomer of the proton pump inhibitor omeprazole and, administered orally, has been evaluated in the management of gastroesophageal reflux disease (GERD) in children aged 1–11 years and adolescents aged 12–17 years. Further studies in children are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics